Tysabri (natalizumab) was found to be superior to interferon beta (IFN-β) in a small, 12-month study with relapsing-remitting multiple sclerosis (RRMS) patients, significantly decreasing their disability ... Read more
The U.S. Food and Drug Administration (FDA) has issued a safety alert, warning that people with relapsing multiple sclerosis (MS) who stop using Gilenya (fingolimod) may experience disease worsening beyond ... Read more
Blood stem cell transplants lead to significant improvements in relapsing-remitting multiple sclerosis patients’ disability, a Phase 3 clinical trial shows. The 110 patients who took part in ... Read more
Multiple sclerosis patients whose first treatment is Genentech’s Rituxan (rituximab) stay on it longer than other disease-modifying drugs that patients start with, a Swedish study reports.
When they ... Read more
People with a demyelinating disease associated with antibodies against a myelin oligodendrocyte glycoprotein (MOG), most often develop episodes of optic neuritis (inflammation of the optic nerve) that can ... Read more
Gilenya decreased relapses in children and adolescents with multiple sclerosis in the phase 3 PARADIGMS trial, according to the therapy’s developer, Novartis.
The Swiss company will present ... Read more
Despite the existence of several disease-modifying drugs for people with relapsing-remitting multiple sclerosis (RRMS), patients’ satisfaction plays a critical role in their adherence to treatment. Improving adherence should ... Read more
A retrospective study of vitamin D status and disability progression in multiple sclerosis patients — using real-life, clinical data from a large and varied group — found no correlation between ... Read more
Dr. Fred Lublin, a renowned multiple sclerosis (MS) expert at Mount Sinai Medical Center, helped launch the Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting, June 1 – 4, ... Read more
The Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting will open with the John F. Kurtzke Memorial Lecture, “Do Relapses Really Matter?”, by the renowned multiple sclerosis ... Read more
EMD Serono, the North American biopharmaceutical business arm of Merck, announced it has gained exclusive rights over Rebif (interferon beta-1a) in the United States. Rebif is a treatment for relapsing ... Read more
The National Multiple Sclerosis Society recently announced that a research team is now recruiting 132 patients with a diagnosis of neuromyelitis optica spectrum disorders (NMOSD) for a ... Read more
Pin It on Pinterest